The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•15 February 2026•

1 min read

DexCom Beats Q4 Estimates with $1.26 Billion Revenue, Reaffirms 2026 Outlook

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

DexCom Inc. (DXCM) reported strong financial results for the fourth quarter of 2025, with revenue reaching $1.26 billion and surpassing Wall Street expectations. The company also announced that its full-year 2025 revenue totaled $4.662 billion, exceeding its previously issued guidance. This robust performance was primarily driven by the successful adoption of the G7 continuous glucose monitoring system and the newly launched Stelo system. Furthermore, DexCom reiterated its revenue guidance for 2026, signaling confidence in its long-term growth trajectory. Management attributed the success to continued product innovation and effective market expansion strategies. Investors reacted positively to the double beat on quarterly and annual figures, reinforcing the company's position in the medical device sector.